Funding Daily Summary
Funding Daily Summary: What Happened on October 5, 2026
Biossil raises $153 million to expand clinical development and acquire drug candidates
Enveda and Anew Labs also raised large rounds, and ARPA-H awarded more than $100 million for biosensor projects.
Today in brief
Biossil secured $153 million in financing led by the OpenAI Startup Fund, giving it a reported $1 billion valuation.1 The company said it will expand clinical development and acquire more drug candidates, including drugs that failed trials.1
Enveda raised $311 million, and Anew Labs raised $290 million in its first outside financing.1
Biossil raises $153 million to expand its drug-revival strategy
A round led by the OpenAI Startup Fund brought Biossil $153 million, with several other investors participating.1 The company said it will use the financing to expand clinical development capacity and obtain additional drug candidates.1
Biossil acquires or licenses drugs that failed trials and assesses whether they might work in a more narrowly selected patient group.1 The round puts the company’s reported valuation at $1 billion, after it raised $70 million when it emerged from stealth.1
Also worth knowing
-
W
Enveda’s $311 million Series E came at a stated $2 billion valuation and will fund three clinical programs.1
-
W
Anew Labs’ first outside financing came at a reported $1.5 billion valuation.1
-
ARPA-H awarded more than $100 million to four organizations developing biosensors to track heart disease, inflammation and perimenopause.2
Also published
- The biggest biotech funding rounds in September 2026 Labiotech
- Fundraising: Why relationships matter more than ever European Biotechnology